Previous 10 | Next 10 |
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clini...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Landos Biopharma Inc. (LABP) is expected to report $-0.79 for Q3 2023
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the t...
NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024 NEW YORK, Sept. 19, 2023 (GL...
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a strategic research collaboration to investigate the effects of NX-13 on epitheli...
2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...
2023-08-10 14:20:32 ET Landos Biopharma press release ( NASDAQ: LABP ): Q2 GAAP EPS of -$0.63. the Company had cash, cash equivalents and marketable securities of $44.7 million, For further details see: Landos Biopharma GAAP EPS of -$0.63
Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NA...
2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...
News, Short Squeeze, Breakout and More Instantly...
Landos Biopharma Inc. Company Name:
LABP Stock Symbol:
NASDAQ Market:
2024-05-26 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AbbVie Completes Acquisition of Landos Biopharma PR Newswire - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill....
NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...